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Abstract
Epstein-Barr virus (EBV), a ubiquitous B-lymphotropic herpesvirus, ectopically infects T or NK cells to cause severe diseases of
unknown pathogenesis, including chronic active EBV infection (CAEBV) and EBV-associated hemophagocytic lymphohis-
tiocytosis (EBV-HLH). We developed xenograft models of CAEBV and EBV-HLH by transplanting patients’ PBMC to
immunodeficient mice of the NOD/Shi-scid/IL-2Rc
null strain. In these models, EBV-infected T, NK, or B cells proliferated
systemically and reproduced histological characteristics of the two diseases. Analysis of the TCR repertoire expression
revealed that identical predominant EBV-infected T-cell clones proliferated in patients and corresponding mice transplanted
with their PBMC. Expression of the EBV nuclear antigen 1 (EBNA1), the latent membrane protein 1 (LMP1), and LMP2, but
not EBNA2, in the engrafted cells is consistent with the latency II program of EBV gene expression known in CAEBV. High
levels of human cytokines, including IL-8, IFN-c, and RANTES, were detected in the peripheral blood of the model mice,
mirroring hypercytokinemia characteristic to both CAEBV and EBV-HLH. Transplantation of individual immunophenotypic
subsets isolated from patients’ PBMC as well as that of various combinations of these subsets revealed a critical role of CD4
+
T cells in the engraftment of EBV-infected T and NK cells. In accordance with this finding, in vivo depletion of CD4
+ T cells by
the administration of the OKT4 antibody following transplantation of PBMC prevented the engraftment of EBV-infected T
and NK cells. This is the first report of animal models of CAEBV and EBV-HLH that are expected to be useful tools in the
development of novel therapeutic strategies for the treatment of the diseases.
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Introduction
Epstein-Barr virus (EBV) is a ubiquitous c-herpesvirus that
infects more than 90% of the adult population in the world. EBV
is occasionally involved in the pathogenesis of malignant tumors,
such as Burkitt lymphoma, Hodgkin lymphoma, and nasopha-
ryngeal carcinoma, along with the post-transplantation lympho-
proliferative disorders in immunocompromised hosts. Although
EBV infection is asymptomatic in most immunologically compe-
tent hosts, it sometimes causes infectious mononucleosis (IM),
when primarily infecting adolescents and young adults [1]. EBV
infects human B cells efficiently in vitro and transform them into
lymphoblastoid cell lines (LCLs) [2]. Experimental infection of T
and NK cells, in contrast, is practically impossible except in limited
conditions [3,4]. Nevertheless, EBV has been consistently
demonstrated in T or NK cells proliferating monoclonally or
oligoclonally in a group of diseases including chronic active EBV
infection (CAEBV) and EBV-associated hemophagocytic lympho-
histiocytosis (EBV-HLH) [5,6,7,8,9,10]. CAEBV, largely overlap-
ping the systemic EBV
+ T-cell lymphoproliferative diseases of
childhood defined in the WHO classification of lymphomas [11],
is characterized by prolonged or relapsing IM-like symptoms,
unusual patterns of antibody responses to EBV, and elevated EBV
DNA load in the peripheral blood [12,13,14]. CAEBV has a
chronic time course with generally poor prognosis; without a
proper treatment by hematopoietic stem cell transplantation, the
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NK lineages, multi-organ failure, or other life-threatening
conditions. Monoclonal or oligoclonal proliferation of EBV-
infected T and NK cells, an essential feature of CAEBV, implies
its malignant nature, but other characteristics of CAEBV do not
necessarily support this notion. For example, EBV-infected T or
NK cells freshly isolated from CAEBV patients, as well as
established cell lines derived from them, do not have morpholog-
ical atypia and do not engraft either in nude mice or scid mice
(Shimizu, N., unpublished results). Clinically, CAEBV has a
chronic time course and patients may live for many years without
progression of the disease [15]. Although patients with CAEBV do
not show signs of explicit immunodeficiency, some of them present
a deficiency in NK-cell activity or in EBV-specific T-cell
responses, implying a role for subtle immunodeficiency in its
pathogenesis [16,17,18].
EBV-HLH is the most common and the severest type of virus-
associated HLH and, similar to CAEBV, characterized by
monoclonal or oligoclonal proliferation of EBV-infected T (most
often CD8
+ T) cells [5,6]. Clinical features of EBV-HLH include
high fever, pancytopenia, coagulation abnormalities, hepatospleno-
megaly, liver dysfunction, and hemophagocytosis [19]. Overpro-
duction of cytokines by EBV-infected T cells as well as by activated
macrophages and T cells reacting to EBV is thought to play a
central role in the pathogenesis [20]. Although EBV-HLH is an
aggressive disease requiring intensive clinical interventions, it may
be cured, in contrast to CAEBV, by proper treatment with
immunomodulating drugs [21]. No appropriate animal models
have been so far developed for either CAEBV or EBV-HLH.
NOD/Shi-scid/IL-2Rc
null (referred here as NOG) is a highly
immunodeficient mouse strain totally lacking T, B, and NK
lymphocytes, and transplantation of human hematopoietic stem cells
to NOG mice results in reconstitution of human immune system
components, including T, B, NK cells, dendritic cells, and
macrophages [22,23]. These so called humanized mice have been
utilized as animal models for the infection of certain human viruses
targeting the hemato-immune system, including human immunode-
ficiency virus 1 (HIV-1) and EBV [24,25,26,27,28,29,30]. Xeno-
transplantation of human tumor cells to NOG mice also provided
model systems for several hematologic malignancies [31,32,33]. To
facilitate investigations on the pathogenesis of CAEBV and EBV-
HLH and assist the development of novel therapeutic strategies, we
generated mouse models of these two EBV-associated diseases by
transplanting NOG mice with PBMC isolated from patients with the
diseases.Inthesemodels,EBV-infectedT,NK,orBcellsengraftedin
NOG mice and reproduced lymphoproliferative disorder similar to
either CAEBV or EBV-HLH. Further experiments with the models
revealed a critical role of CD4
+ T cells in the in vivo proliferation of
EBV-infected T and NK cells.
Results
Engraftment of EBV-infected T and NK cells in NOG mice
following xenotransplantation with PBMC of CAEBV
patients
Depending on the immunophenotypic subset in which EBV
causes lymphoproliferation, CAEBV is classified into the T-cell
and NK-cell types, with the former being further divided into the
CD4, CD8, and cdT types. The nine patients with CAEBV
examined in this study are characterized in Table 1 and include all
these four types. Intravenous injection of 124610
6 PBMC
isolated from these nine patients resulted in successful engraftment
of EBV-infected T or NK cells in NOG mice in a reproducible
manner (Table 1). The results with the patient 1 (CD4 type),
patient 3 (CD8 type), patient 5 (cdT type), and patient 9 (NK type)
are shown in Figure 1. Seven to nine weeks post-transplantation,
EBV DNA was detected in the peripheral blood of recipient mice
and reached the levels of 10
5–10
8 copies/mg DNA (Figure 1A). By
contrast, no engraftment of EBV-infected cells was observed when
immunophenotypic fractions containing EBV DNA were isolated
from PBMC and injected to NOG mice (Figure 1A and Table 2).
An exception was the CD4
+ T-cell fraction isolated from patients
with the CD4 type CAEBV, that reproducibly engrafted when
transplanted without other components of PBMC (Figure 1A,
Table 2). Flow cytometry revealed that the major population of
engrafted cells was either CD4
+, CD8
+, TCRcdor CD16
+CD56
+,
depending on the type of the donor CAEBV patient (Figure 1B).
EBV-infected cells of identical immunophenotypes were found in
the patients and the corresponding mice that received their
respective PBMC (Figure 1B). Although human cells of multiple
immunophenotypes were present in most recipient mice, fraction-
ation by magnetic beads-conjugated antibodies and subsequent
real-time PCR analysis detected EBV DNA only in the
predominant immunophenotypes that contained EBV DNA in
the original patients (Figure 1B, Table 1). The EBV DNA load
observed in individual lymphocyte subsets in the patient 3 and a
mouse that received her PBMC is shown as supporting data (Table
S1). When PBMC from three healthy EBV-carriers were injected
intravenously to NOG mice, as controls, no EBV DNA was
detected from either the peripheral blood, spleen, or liver (data not
shown). Histological analyses of the spleen and the liver of these
control mice identified no EBV-encoded small RNA (EBER)-
positive cells, although some CD3-positive human T cells were
observed (Figure S2). Analysis of TCR Vb repertoire demonstrat-
ed an identical predominant T-cell clone in patients (patients 1
and 3) and the corresponding mice that received their PBMC
(Figure 1C). The general condition of most recipient mice
deteriorated gradually in the observation period of eight to twelve
weeks, with loss of body weight (Figure S1), ruffled hair, and
inactivity.
NOG mice engrafted with EBV-infected T or NK cells were
sacrificed for pathological and virological analyses between eight
Author Summary
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus
that infects more than 90% of the adult human population
in the world. EBV usually infects B lymphocytes and does
not produce symptoms in infected individuals, but in rare
occasions it infects T or NK lymphocytes and causes severe
diseases such as chronic active EBV infection (CAEBV) and
EBV-associated hemophagocytic lymphohistiocytosis (EBV-
HLH). We developed mouse models of these two human
diseases in which EBV-infected T or NK lymphocytes
proliferate in mouse tissues and reproduce human
pathologic conditions such as overproduction of small
proteins called ‘‘cytokines’’ that produce inflammatory
responses in the body. These mouse models are thought
to be very useful for the elucidation of the pathogenesis of
CAEBV and EBV-HLH as well as for the development of
therapeutic strategies for the treatment of these diseases.
Experiments with the models demonstrated that a subset
of lymphocytes called CD4-positive lymphocytes are
essential for the proliferation of EBV-infected T and NK
cells. This result implies that removal of CD4-positive
lymphocytes or suppression of their functions may be an
effective strategy for the treatment of CAEBV and EBV-
HLH.
Mouse Xenograft Models for CAEBV and EBV-HLH
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of mice presented with splenomegaly, with slight hepatomegaly in
occasional cases (Figure 2A). Histopathological findings obtained
from a representative mouse (recipient of PBMC from the patient
3 (CD8 type)) are shown in Figure 2B and reveal infiltration of
human CD3
+CD20
2 cells to major organs, including the spleen,
liver, lungs, kidneys, and small intestine. These cells were positive
for both EBER and human CD45RO, indicating that they are
EBV-infected human T cells (Figure 2B). In contrast, no EBV-
infected T cells were found in mice transplanted with PBMC
isolated from a normal EBV carrier (Figure S2). Histopathology of
a control NOG mouse is shown in Figure S2. Morphologically,
EBV-infected cells are relatively small and do not have marked
atypia. The infiltration pattern was leukemic and identical with
chronic active EBV infection in children [34]. The architecture of
the organs was well preserved in spite of marked lymphoid
infiltration. The spleen showed marked expansion of periarterial
lymphatic sheath owing to lymphocytic infiltration. In the liver, a
dense lymphocytic infiltration was observed in the portal area and
in the sinusoid. The lung showed a picture of interstitial
pneumonitis and the lymphocytes often formed nodular aggrega-
tions around bronchioles and arteries. In the kidney, dense
lymphocytic infiltration caused interstitial nephritis. In the small
intestine, mild lymphoid infiltration was seen in mucosa.
Quantification of EBV DNA in the spleen, liver, lymph nodes,
lungs, kidneys, adrenals, and small intestine of this mouse revealed
EBV DNA at the levels of 1.5–5.1610
7 copies/mg DNA. Mice
transplanted with PBMC derived from CAEBV of other types
exhibited similar infiltration of EBV-infected T or NK cells to the
spleen, liver, and other organs (Figure 2C and data not shown).
EBV-infected T- and NK-cell lines established from CAEBV
patients do not engraft in NOG mice
We established EBV-positive cell lines of CD4
+ T, CD8
+ T,
cdT, and CD56
+ NK lineages from PBMC of the patients listed in
Table 1 by the method described previously [35], and confirmed
by flow cytometry that the surface phenotypes of EBV-infected
cells in the original patients were retained in these cell lines (data
not shown). To test whether these cell lines engraft in NOG mice,
1–4610
6 cells were injected intravenously to NOG mice. The
results are shown in Figure 3A and indicate that CAEBV-derived
cell lines of the CD8
+ T, cdT, and CD56
+ NK phenotypes do not
engraft in NOG mice. Neither human CD45-positive cells nor
EBV DNA were detected in the peripheral blood of the mice up to
twelve weeks post-transplantation. When the recipient mice were
sacrificed at twelve weeks post-injection, no EBV DNA could be
detected in the spleen, liver, bone marrow, mesenteric lymph
nodes, and kidneys. In contrast, the CD4
+ T cell lines derived from
the CD4-type patients 1 and 2 engrafted in NOG mice and
induced T lymphoproliferation similar to that induced by PBMC
isolated freshly from these patients (Figure 3A and data not
shown). These results, together with the results of transplantation
with EBV-containing subsets of PBMC, indicate that EBV-
infected T and NK cells, with the exception of those of the
CD4
+ subset, are not able to engraft in NOG mice, when they are
separated from other components of PBMC, suggesting that some
components of PBMC are essential for the outgrowth EBV-
infected T and NK cells in NOG mice.
Engraftment of EBV-infected T and NK cells in NOG mice
requires CD4
+ T cells
To identify the cellular component required for the engraftment
of EBV-infected T and NK cells in NOG mice, we transplanted
PBMC of CAEBV patients after removing individual immuno-
phenotypic subsets by magnetic beads-conjugated antibodies. The
results are shown in Figure 3B and summarized in Table 2. With
respect to the patients 3 and 4, in whom CD8
+ T cells are infected
with EBV, removal of CD8
+ cells from PBMC, as expected,
resulted in the failure of engraftment, whereas elimination of
CD19
+, CD56
+, or CD14
+ cells did not affect engraftment.
Importantly, elimination of CD4
+ cell fraction, that did not
contain EBV DNA, resulted in the failure of engraftment of EBV-
infected T cells (Figure 3B and data not shown). In the
experiments with the patients 5 and 6, in whom cdT cells were
infected, removal CD4
+ cells that did not contain EBV DNA, as
well as that of cdT cells, resulted in the failure of engraftment.
Table 1. Patients with EBV-T/NK LPD and the results of xenotransplantation of their PBMC to NOG mice.
Patient
number Diagnosis Sex Age
Type of
infected cells
1EBV DNA load in
the patients
2Engrafted cells
in mice
3Engraftment
1EBV DNA load
in mice
1 CAEBV F 25 CD4 9.2610
5 CD4, CD8 3/3 1.0,3.8610
7
2 CAEBV M 46 CD4 1.3,7.2610
5 CD4, CD8 2/2, 3/3 2.6,10610
5
3 CAEBV F 35 CD8 2.1,78610
5 CD8, CD4 2/2, 2/2 1.1,33610
6
4 CAEBV M 28 CD8 8.2610
5 CD8, CD4 3/3 1.1,2.5610
6
5 CAEBV M 10 cdT 2.2610
6 cdT, CD4, CD8 2/2 3.8,6.5610
6
6 CAEBV F 15 cdT 6.2610
5 cdT, CD4, CD8 2/2 2.2,11610
5
7 CAEBV M 13 NK 1.1,6.7610
5 NK, CD4, CD8 2/2, 2/2 0.6,15610
4
8 CAEBV F 13 NK 6.3610
6 NK, CD4, CD8 3/3, 2/2 0.8,1.9610
5
9 CAEBV M 8 NK 1.2,8.7610
5 NK, CD4, CD8 2/2, 3/3 1.8,7.2610
5
10 EBV-HLH M 10 CD8 2.8,38610
4 CD8, CD4 2/2, 2/2 6.5,9.9610
4
11 EBV-HLH M 50 CD8 6.2610
5 CD8, CD4 4/4 7.0,45610
4
12 EBV-HLH M 1 CD8 3.1610
5 CD8, CD4 2/2 6.0,9.1610
4
13 EBV-HLH M 64 CD8 3.2,3.9610
5 CD8, CD4 2/2, 2/2 5.0,30610
5
1EBV DNA copies/mg DNA in the peripheral blood.
2EBV DNA was detected only in the cells of the underlined subsets.
3Number of mice with successful engraftment per number of recipient mice is shown for each experiment.
doi:10.1371/journal.ppat.1002326.t001
Mouse Xenograft Models for CAEBV and EBV-HLH
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+, CD14
+, CD19
+, or CD56
+ cells did not have
an influence on the engraftment (Figure 3B and data not shown).
Regarding the patients 8 an 9 in whom EBV resided in CD56
+
NK cells, removal of CD4
+ as well as CD56
+ cells resulted in the
failure of engraftment, whereas that of CD8
+, CD19
+, or CD14
+
cells did not affect engraftment (Figure 3B and data not shown). In
Figure 1. Engraftment of EBV-infected T or NK cells in NOG mice following transplantation with PBMC of patients with CAEBV. A.
Measurement of EBV DNA levels. PBMC obtained from the CAEBV patients 1 (CD4 type), 3 (CD8 type), 5 (cdT type), and 9 (NK type) were injected
intravenously to NOG mice and EBV DNA load in their peripheral blood was measured weekly by real-time PCR. The results of transplantation with
whole PBMC or with isolated EBV DNA-containing cell fraction are shown. B. Flow-cytometric analysis on the expression of surface markers in the
peripheral blood lymphocytes of patients (a) with CAEBV and NOG mice (b) that received PBMC from them. Human lymphocytes gated by the pattern
of side scatter and human CD45 expression were further analyzed for the expression of various surface markers indicated in the figures. The results
from the patients 1, 3, 5, and 9, and the corresponding mice that received their respective PBMC are shown. Circles indicate the fractions that
contained EBV DNA. C. Analysis on the expression of TCR Vb repertoire. Peripheral blood lymphocytes obtained from the patients 1 (CD4 type) and 3
(CD8 type), and from the corresponding mice that received their respective PBMC were analyzed for the expression of Vb alleles. The percentages of T
cells expressing each Vb allele are shown for the patients (grey bars) and the mice (black bars).
doi:10.1371/journal.ppat.1002326.g001
Mouse Xenograft Models for CAEBV and EBV-HLH
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+ T cells were infected, only the
removal of CD4
+ cells blocked the engraftment of EBV-infected
cells and depletion of either CD8
+, CD19
+, or CD14
+ cells had no
effect (Figure 3B and data not shown). These results suggested that
EBV-infected cells of the CD8
+, cdT, and CD56
+ lineages require
CD4
+ cells for their engraftment in NOG mice. To confirm this
interpretation, we performed complementation experiments, in
which EBV-containing fractions of the CD8
+ (patient 4), cdT
(patient 5), or CD56
+ (patient 7) phenotypes were transplanted
together with autologous CD4
+ cells. The results are shown in
Figure 3A and indicate that EBV-infected CD8
+, cdT, or CD56
+
cells engraft in NOG mice when transplanted together with CD4
+
cells. Similarly, when EBV-infected cell lines of the CD8
+, cdT,
and CD16
+ lineages were injected intravenously to NOG mice
together with autologous CD4
+ cells, these cell lines engrafted to
the mice (Figure 3A). Finally, to further confirm the essential role
of CD4
+ cells, we examined the effect of the OKT-4 antibody that
depletes CD4
+ cells in vivo [24]. PBMC isolated from the CAEBV
patient 3 (CD8 type) and the patient 8 (NK type) were injected
intravenously to NOG mice and OKT-4 was administered
intravenously for four consecutive days starting from the day of
transplantation. The results are shown in Figure 4 and indicate
that OKT-4 can strongly suppress the engraftment of EBV-
infected T and NK cells. In the mice treated with OKT-4, no
splenomegaly was observed and EBV DNA was not detected
either in the peripheral blood, spleen, liver, or lungs at eight weeks
post-transplantation.
Analysis on the EBV gene expression associated with T or
NK lymphoproliferation in NOG mice
Previous analysis of EBV gene expression in patients with
CAEBV revealed the expression of EBNA1, LMP1, and LMP2A
with the involvement of the Q promoter in the EBNA genes
transcription and no expression of EBNA2, being consistent with
the latency II type of EBV gene expression [36,37,38]. To test
whether EBV-infected T and NK cells that proliferate in NOG
mice retain this type of viral gene expression, we performed RT-
PCR analysis in the spleen and the liver of mice that received
Table 2. Results of xenotransplantation with subsets of PBMC obtained from CAEBV patients.
Number
of patient Diagnosis
Phenotype of
infected cells
Cell fraction
transplanted
Number of
transplanted cells Engraftment
1 CAEBV CD4 PBMC 2610
6 +
CD4 2610
6 +
PBMC-CD4 3610
6 2
PBMC-CD8 2610
6 +
PBMC-CD56 2610
6 +
PBMC-CD14 2610
6 +
PBMC-CD19 2610
6 +
3 CAEBV CD8 PBMC 2610
6 +
CD8 3610
6 2
PBMC-CD4 3610
6 2
PBMC-CD8 3610
6 2
PBMC-CD56 2610
6 +
PBMC-CD14 2610
6 +
PBMC-CD19 2610
6 +
5 CAEBV cdT PBMC 2610
6 +
cdT3 610
6 2
PBMC-CD4 3610
6 2
PBMC-cdT3 610
6 2
PBMC- CD8 3610
6 +
PBMC-CD56 3610
6 +
PBMC-CD14 3610
6 +
PBMC-CD19 3610
6 +
9 CAEBV NK PBMC 2610
6 +
NK 3610
6 2
PBMC-CD4 3610
6 2
PBMC-CD8 3610
6 +
PBMC-CD56 3610
6 2
PBMC-CD14 3610
6 +
PBMC-CD19 3610
6 +
11 EBV-HLH CD8 PBMC 2610
6 +
PBMC-CD4 4610
6 2
doi:10.1371/journal.ppat.1002326.t002
Mouse Xenograft Models for CAEBV and EBV-HLH
PLoS Pathogens | www.plospathogens.org 5 October 2011 | Volume 7 | Issue 10 | e1002326Figure 2. Pathological and immunochemical analyses on NOG mice transplanted with PBMC from CAEBV patients. A. Photographs of
a model mouse showing splenomegaly and of the excised spleen. This mouse was transplanted with PBMC from the CAEBV patient 3 (CD8 type).
Spleen from a control NOG mouse is also shown. B. Photomicrographs of various tissues of a mouse that received PBMC from the patient 3 (CD8
type). Upper panels: liver tissue was stained with hematoxylin-eosin (HE), antibodies specific to human CD3 or CD20, or by ISH with an EBER probe;
the rightmost panel is a double staining with EBER and human CD45RO. Bottom panels: EBER ISH in the spleen, kidney, lung, and small intestine.
Original magnification is6200, except for EBER/CD45RO, that is6400. C. Photomicrographs of the spleen and liver tissues obtained from NOG mice
transplanted with PBMC from the CAEBV patients 2 (CD4 type), 6 (cdT type) or 7 (NK type). Tissues were stained by EBER-ISH or by double staining
with EBER-ISH and human CD45RO. Original magnification 6600.
doi:10.1371/journal.ppat.1002326.g002
Mouse Xenograft Models for CAEBV and EBV-HLH
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shown in Figure 5A and demonstrate the expression of mRNAs
coding for EBNA1, LMP1, LMP2A, and LMP2B, but not for
EBNA2. Expression of the EBV-encoded small RNA 1 (EBER1)
was also demonstrated. EBNA1 mRNAs transcribed from either
the Cp promoter or the Wp promoter were not detected, whereas
those transcribed from the Q promoter was abundantly detected.
These results indicate that EBV-infected T cells retain the latency
Figure 3. Analysis on the conditions of the engraftment of EBV-infected T and NK cells in NOG mice. A. EBV-infected T or NK cells
isolated from patients with CAEBV or cell lines derived from them were injected to NOG mice in the conditions described below. Peripheral blood EBV
DNA levels were then measured weekly. Upper-left panel: 5610
6 cells of EBV-infected CD4
+ T, CD8
+ T, cdT, and CD56
+ NK cell lines established from
the CAEBV patients 1, 4, 6, and 8, respectively, were injected intravenously to NOG mice. Upper-right panel: 5610
6 cells of the CD8
+ T, cdT, and CD56
+
NK cell lines established from the patients 3, 6, and 8, respectively, were injected intravenously to NOG mice together with autologous CD4
+ T cells
isolated from 5610
6 PBMC. Bottom panel: 5610
6 cells of the CD8
+ T, cdT, and CD56
+ NK fractions isolated freshly from the patients 4, 5, and 7,
respectively, were injected intravenously to NOG mice together with autologous CD4
+ T cells isolated from 5610
6 PBMC. B. Transplantation of PBMC
devoid of individual immunophenotypic subsets to NOG mice. CD19
+, CD4
+, CD8
+, CD56
+, or CD14
+ cells were removed from PBMC obtained from
the patient 1 (CD4 type, upper-left panel), 4 (CD8 type, upper-right), 5 (cdT type, bottom-left), and 9 (NK type, bottom-right) and the remaining cells
were injected intravenously to NOG mice. Thereafter peripheral blood EBV DNA was determined weekly.
doi:10.1371/journal.ppat.1002326.g003
Mouse Xenograft Models for CAEBV and EBV-HLH
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NOG mice. Similar analyses with NOG mice engrafted with EBV-
infected NK cells also showed the latency II type of EBV gene
expression (data not shown).
NOG mice engrafted with EBV-infected T or NK cells
produce high levels of human cytokines
In patients with CAEBV, high levels of cytokines have been
detected in the peripheral blood and are thought to play important
roles in the pathogenesis [20,39,40]. To test whether this hypercy-
tokinemia is reproduced in NOG mice, we examined the levels of
various human cytokines in the sera of transplanted mice using
ELISAkits thatcan quantify human cytokinesspecifically. Theresults
are shown in Figure 5B and indicate that the mice transplanted with
PBMC of the patient 3 (CD8 type) or the patient 8 (NK type)
contained high levels of RANTES, IFN-c, and IL-8 in their sera.
Engraftment of EBV-infected T and B cells derived from
patients with EBV-HLH in NOG mice
To extend the findings obtained from the CAEBV xenograft
model to another disease with EBV
+ T/NK lymphoproliferation,
we transplanted NOG mice with PBMC isolated from patients
with EBV-HLH. Characteristics of the four EBV-HLH patients
examined in this study and the results of transplantation with their
PBMC are summarized in Table 1. EBV DNA was detected in the
peripheral blood three to four weeks post-transplantation and
rapidly reached the levels of 1610
4 to 1610
6 copies/mg DNA
(results of typical experiments are shown in Figure 6A). Similar to
the findings in CAEBV, EBV DNA was not detected in the
recipient mice, when CD4
+ cell fraction was removed from PBMC
(Figure 6A). Immunophenotypic analyses on the peripheral blood
lymphocytes isolated from EBV-HLH patients and corresponding
recipient mice revealed that cells of an identical immunophe-
notype (CD3
+CD8
+CD45RO
+CD19
2CD4
2CD45RA
2CD16
2-
CD56
2) were present and contained EBV DNA in both the
patients and corresponding mice (Figure 6C and data not shown).
The EBV DNA load observed in individual lymphocyte subsets in
the patient 10 and a mouse that received his PBMC is shown as
supporting data (Table S2). General condition of the recipient
mice deteriorated consistently more quickly, with the loss of body
weight (Figure S1), ruffling of hair, and general inactivity, than
those mice engrafted with EBV-infected T or NK cells derived
from CAEBV. The mice were sacrificed around four weeks post-
transplantation for pathological analyses. Macroscopical observa-
tion revealed moderate to severe splenomegaly (Figure 6D) in the
Figure 4. Suppression of the engraftment of EBV-infected T and NK cells by the OKT-4 antibody. PBMC (5610
6 cells) isolated from the
CAEBV patient 3 (CD8 type) or 8 (NK type) were injected intravenously to NOG mice. The OKT-4 antibody (100 mg/mouse) was administered
intravenously on the same day of transplantation and the following three consecutive days. As a control, isotype-matched mouse IgG was injected. A.
Changes in the peripheral blood EBV DNA level in the recipient mice. Results with the mice transplanted with PBMC of the patient 3 (top) and of the
patient 8 (bottom) are shown. B. Photographs of the spleen of an OKT-4-treated mouse (top) and a control mouse (bottom) taken at autopsy.
doi:10.1371/journal.ppat.1002326.g004
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fraction of them. A finding characteristic to these mice were
massive hemorrhages in the abdominal and/or thoracic cavities,
that were not seen in the mice transplanted with CAEBV-derived
PBMC (Figure 6D and data not shown). These hemorrhagic
lesions may reflect coagulation abnormalities characteristic to
Figure 5. Analyses on the latent EBV gene expression and cytokine production in NOG mice transplanted with PBMC of CAEBV
patients. A. EBV gene expression. Total RNA was purified from the spleen and liver of a mouse that received PBMC from the patient 3 (CD8 type) and
applied for RT-PCR assay to detect transcripts from the indicated genes. RNA samples from an EBV-transformed B-lymphoblastoid cell line (LCL) and
from EBV-negative Akata cell line were used as positive and negative controls, respectively. The primers used in the experiments are shown in
Materials and Methods. B. Quantification of plasma levels of human cytokines in patients with CAEBV and corresponding recipient mice. PBMC were
isolated from the patients 3 (CD8 type) and 8 (NK type) in two occasions and transplanted to NOG mice. Plasma cytokine levels of the patients were
determined when their PBMC were isolated. Plasma cytokine levels of the corresponding recipient mice, prepared on each occasion of PBMC
collection, were determined when they were sacrificed. Concentration of human IL-8, IFN-c, and RANTES were measured by appropriate ELISA kits
following the instruction provided by the manufacturer. Plasma samples from healthy adults were used as a control. The bars represent mean values
and standard errors from triplicate measurements.
doi:10.1371/journal.ppat.1002326.g005
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+
cells in the spleen and the liver (Figure 6E) and quantification of
EBV DNA in these tissues revealed 1.4610
1 to 2.4610
2 copies/mg
of EBV DNA. When the tissues were examined by immunostain-
ing and EBER ISH, the EBER
+ cells were shown unexpectedly to
be mostly CD45RO
- and CD20
+ in all five transplantation
experiments with four different patients, indicating that the
majority of EBV-infected cells in these tissues are of the B-cell
lineage (Figure 6E and data not shown). EBER
+ large B cells were
seen scattered among numerous reactive small T cells, most of
which are CD8
+, in the tissues of the spleen, liver, lungs and
kidneys. A number of macrophages were also seen in these tissues.
Fractionation of mononuclear cells obtained from the liver of a
mouse transplanted with PBMC of the EBV-HLH patient 10,
followed by real-time PCR, detected EBV DNA (1.4610
1 copies/
mgD N A )o n l yi nt h eC D 1 9
+ B-cell fraction. In addition, an EBV-
infected B lymphoblastoid cell line, but not an EBV-positive T
cell line, could be established from this liver. Thus the presence of
EBV in B cells were demonstrated by three independent methods
in the tissues of EBV-HLH mice. Enzyme-linked immunosorbent
assay revealed extremely high levels of human cytokines,
including IL-8, IFN-c, and RANTES, in the sera of both the
original patients and the recipient mice (Figure 6B). The levels of
IL-8 and IFN-c were much higher than those observed in the
peripheral blood of patients with CAEBV and mice that received
their PBMC. Thus, NOG mice transplanted with EBV-HLH-
derived PBMC are distinct from those transplanted with CAEBV-
derived PBMC in the aggressive time course of the disease, internal
hemorrhagic lesions, extremely high levels of IL-8 and IFN-c in the
peripheral blood, and the presence of EBV-infected B cells in
lymphoid tissues.
Discussion
The mouse xenograft models of CAEBV and EBV-HLH
developed here represent the first recapitulation of EBV-associated
T/NK lymphoproliferation in experimental animals. Previously,
Hayashi and others inoculated rabbits with Herpesvirus papio and
succeeded in the generation of T-cell lymphoproliferative disorder
with pathological findings suggestive of EBV-HLH [41]. This
model, however, is based on an EBV-related virus and not EBV
itself, and therefore may contain features irrelevant to the original
human disease. Although the CAEBV and EBV-HLH models
described here exhibited some common features, including the
abundant presence of EBV-infected T or NK cells in the
peripheral blood, there were some critical differences between
the two models, probably reflecting the divergence of the
pathophysiology of the original diseases. First of all, in the EBV-
HLH model mouse, EBV was detected mainly in B cells in the
spleen and the liver, while it was found mainly in T cells in the
peripheral blood. This makes an obvious contrast with the
CAEBV model mouse, where EBV was detected in T or NK
cells in both the peripheral blood and lymphoid tissues. We do not
have an explanation for the apparent discrepancy in the host cell
type of EBV infection between the peripheral blood and lymphoid
tissues of the EBV-HLH model. It should be, however, noted that
histopathology of EBV-HLH tissues has not been fully investigated
and therefore it is still possible that significant number of EBV-
infected B cells are present in the lymphoid tissues of EBV-HLH
patients. Other differences between the two models include much
higher plasma levels of IL-8 and IFN-c more aggressive and fatal
outcome, and internal hemorrhagic lesions in EBV-HLH model
mice, probably reflecting the differences in the pathophysiology of
the original diseases.
EBV-positive B-cell proliferation was not seen in CAEBV model
mice even in long-term observation beyond twelve weeks. This
seems puzzling since low but significant amount of EBV DNA was
found also in B19
+ B-cell fraction in most patients with CAEBV. It
should be noted that EBV-infected T or NK cell lines could be
established relatively easily from patients with CAEBV by adding
recombinant IL-2 in the medium. In contrast, establishment of
EBV-infected B LCLs from these patients has been extremely
difficult. In fact, we could establish B-LCLs from a few patients
with CAEBV only when their PBMC were cultured on feeder cells
expressing CD40 ligand. Therefore, we speculate that in the
particular context of CAEBV, both in the patient and the model
mouse, proliferation of EBV-infected B cells are somehow
inhibited by an unknown mechanism.
Analysis on the conditions of engraftment of EBV-infected T/
NK cells using these new xenograft models revealed that EBV-
infected T and NK cells of the CD8
+ T, TCRcdT and CD56
+ NK
lineages and cell lines derived from them require CD4
+ T cells for
their engraftment in NOG mice. Only those EBV-infected cells
and cell lines of the CD4
+ T lineage could engraft in NOG mice
on their own. These findings suggest that some factor(s) provided
by CD4
+ cells are essential for engraftment. Soluble factors
produced by CD4
+ T cells may be responsible for this function and
we are currently examining cytokines, including IL-2, for their
ability to support the engraftment of EBV-infected T and NK
cells. It is also possible that cell to cell contact involving CD4
+ cells
is critical for engraftment. This dependence on CD4
+ cells
represents an interesting consistency with the previous finding
that engraftment of EBV-transformed B lymphoblastoid cells in
scid mice required the presence of CD4
+ cells [42,43]. It has been
speculated that T cells activated by an EBV-induced superantigen
may be involved in the engraftment of EBV-infected B
lymphoblastoid cells in scid mice [44]. Although a similar
superantigen-mediated mechanism might also be assumed in T-
and NK-cell lymphoproliferation in NOG mice, the data of TCR
repertoire analyses (Figure 1C and data not shown) show no
indication for clonal expansion of Vb13 T cells that are known to
be specifically activated by the EBV-induced superantigen HERV-
K18. It seems therefore unlikely that this superantigen is involved
in the CD4
+ T cell-dependent engraftment of EBV-infected T and
NK cells. We expect CD4
+ T cells and/or molecules produced by
them may be an excellent target in novel therapeutic strategies for
the treatment of CAEBV and EBV-HLH. In fact, administration
of the OKT-4 antibody that depletes CD4
+ cells in vivo efficiently
prevented the engraftment of EBV-infected T cells. As a next step,
we plan to test the effect of post-engraftment administration of
OKT-4.
The dependence of EBV-infected T and NK cells on CD4
+ T
cells for their engraftment in NOG mice suggests the possibility
that these cells are not capable of autonomous proliferation.
Consistent with this notion, EBV-infected T and NK cell lines,
including that of the CD4
+ lineage, are dependent on IL-2 for
their in vitro growth and do not engraft in either nude mice or scid
mice when transplanted either s.c. or i.v (Shimizu, N., unpublished
results). Clinically, CAEBV is a disease of chronic time course and
patients carrying monoclonal EBV-infected T or NK cell
population may live for many years without progression of the
disease [15]. Overt malignant T or NK lymphoma usually
develops only after a long course of the disease. Taking all these
findings in consideration, we suppose that EBV-infected cells are
not truly malignant at least in the early phase of the disease, even
when they appear monoclonal. Because infection of EBV in T or
NK cells is not unique to CAEBV and has been recognized also in
infectious mononucleosis [45,46], the critical deficiency in
Mouse Xenograft Models for CAEBV and EBV-HLH
PLoS Pathogens | www.plospathogens.org 10 October 2011 | Volume 7 | Issue 10 | e1002326Figure 6. Engraftment of EBV-infected T and B cells in NOG mice transplanted with PBMC of patients with EBV-HLH. A. Peripheral
blood EBV DNA load. Following transplantation with PBMC or PBMC devoid of CD4
+ cells of the patient 11, EBV DNA was measured weekly by real-
time PCR. Results of two mice prepared in an experiment are shown. B. Cytokine levels in the peripheral blood of the patient 12 and a mouse that
received his PBMC. The levels of IL-8, IFN-c, and RANTES were measured by ELISA in triplicates and the means and the standard errors are shown. A
plasma sample of healthy person was used as a control. C. Immunophenotypic analyses on the peripheral blood lymphocytes of the EBV-HLH patient
10 (a) and a mouse that received his PBMC (b). Lymphocytes were gated by the pattern of the side scatter and the expression of human CD45, and
analyzed for the expression of the indicated markers. The circles indicate the fractions that contained EBV DNA. D. Photograph of a mouse showing
splenomegaly (red arrow) and hemorrhagic lesions (yellow arrow). Spleens excised from this mouse and a control mouse are shown at the bottom. E.
Photomicrographs of the tissues of mice transplanted with EBV-HLH-derived PBMC. Liver and spleen tissues of a mouse transplanted with PBMC of
the patient 11 were examined by EBER-ISH (left), double staining with an anti-human CD20 monoclonal antibody and EBER-ISH (middle), and double
staining with an anti-human CD45RO monoclonal antibody and EBER-ISH (right). Original magnification 6600.
doi:10.1371/journal.ppat.1002326.g006
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infected T and NK cells. In this context, it should be emphasized
that EBV-infected T or NK cells usually exhibit the latency II
pattern of EBV gene expression and do not express EBNA3s, that
possess immuno-dominant epitopes recognized by EBV-specific T
cells [47]. EBV-infected T and NK cells are thus not likely to be
removed by cytotoxic T cells as efficiently as EBV-infected B cells
that express EBNA3s. The reported lack of cytotoxic T cells
specific to LMP2A [17], one of the few immuno-dominant EBV
proteins expressed in the virus-infected T and NK cells, may
therefore seriously affect the host’s capacity to control their
proliferation. A genetic defect in the perforin gene was recently
identified in a patient with clinical and pathological features
resembling CAEBV, suggesting that defects in genes involved in
immune responses can result in clinical conditions similar to
CAEBV [48].
Engraftment of EBV-infected T and NK cells in NOG mice was
in most cases accompanied by co-engraftment of un-infected cell
populations. These un-infected cells might have been maintained
and induced to proliferate by certain factors produced by EBV-
infected T or NK cells. Abundant cytokines produced by these
cells may be responsible for this activity. It is also possible that the
proliferation of these un-infected cells represents immune
responses. Experiments are underway to test whether these un-
infected T cells contain EBV-specific cells. These un-infected T
cells might also be reacting to host murine tissues. Intravenous
injection of PBMC obtained from normal humans to immunode-
ficient mice including NOG mice has been shown to induce acute
or chronic graft versus host disease (GVHD) [49,50]. However,
because much less PBMC were injected to mice in the present
study as compared to those previous studies, it is not likely that
major GVHD was induced in NOG mice transplanted with
PBMC of patients with CAEBV or EBV-HLH.
CAEBV has been treated by a variety of regimens, including
antiviral, cytocidal, and immunomodulating agents with more or
less unsatisfactory results. Although hematopoietic stem cell
transplantation, especially that with reduced intensity conditioning
can give complete remission in a substantial number of patients
[51,52], it is still desirable to develop safer and more effective
treatment, possibly with pharmaceutical agents. The xenograft
model of CAEBV generated in this study may be an excellent
animal model to test novel experimental therapies for the disease.
In fact, the OKT-4 antibody that depletes CD4
+ T cells in vivo
gave a promising result implying its effectiveness as a therapeutic
to CAEBV.
Materials and Methods
Ethics statement
Protocols of the experiments with materials obtained from
patients with CAEBV and EBV-HLH and from control persons
have been reviewed and approved by the Institutional Review
Boards of the National Center for Child Health and Development
and of the National Institute of Infectious diseases (NIID). Blood
samples of the patients and control persons were collected after
obtaining written informed consent. Protocols of the experiments
with NOG mice are in accordance with the Guidelines for Animal
Experimentation of the Japanese Association for Laboratory
Animal Science and were approved by the Institutional Animal
Care and Use Committee of NIID.
Patients with CAEBV and EBV-HLH
Characteristics of the nine patients with CAEBV and the four
patients with EBV-HLH examined in this study are summarized
in Table 1. Diagnosis of CAEBV and EBV-HLH was made on the
basis of the published guidelines [19,53] and confirmed by
identification of EBV-infected T or NK cells in their peripheral
blood by flow cytometry and real-time PCR.
NOD/Shi-scid/IL2Rc
null (NOG) mice
Mice of the NOD/Shi-scid/IL-2Rc
null (NOG) strain [22] were
obtained from the Central Institute for Experimental Animals
(Kawasaki, Japan) and maintained under specific pathogen free
(SPF) conditions in the animal facility of NIID, as described [22].
Transplantation of PBMC or their subfractions to NOG
mice
PBMC were isolated by centrifugation on Lymphosepar I
(Immuno-Biological Laboratories (IBL)) and injected intravenously
to the tail vein of NOG mice at the age of 6–8 weeks. Depending on
therecovery ofPBMC, 1–4610
6 cellswereinjected to 2 to 4 mice in
a typical experiment with a blood sample. For transplantation with
individual cellular fractions containing EBV DNA, CD4
+ T cells,
CD8
+ T cells, and CD56
+ NK cells were separated with the IMag
Cell Separation Systems (BD Pharmingen) following the protocol
supplied by the manufacturer. To isolate cdT cells, CD19
+, CD4
+,
CD8
+, CD56
+, and CD14
+ cells were serially removed from PBMC
by the IMag Cell Separation Systems. From the remaining
CD19
2CD4
2CD8
2CD56
2CD14
2 population, CD3
+ cells were
positively selected by the same kit and defined as the cdT cell
fraction. To transplant PBMC lacking individual immunopheno-
typic subsets, CD19
+, CD4
+, CD8
+, CD56
+ or CD14
+ cells were
removed from PBMC by the IMag Cell Separation Systems and the
remaining cells were injected to mice. To prepare PBMC lacking
cdT cells, CD19
+, CD4
+, CD8
+, CD56
+, and CD14
+ cells isolated
from PBMC in the process of obtaining cdT cell fraction (see above)
were pooled and mixed with the CD19
2CD4
2CD8
2CD56
2-
CD14
2 cells that did not react with anti-CD3 antibody. For
complementation experiments, an EBV-containing cell fraction and
the CD4
+ cell fraction were isolated from a sample of PBMC as
described above and the mixture of these two fractions were injected
to NOG mice. The approximate numbersofinjected cells are shown
in Table 2.
Analysis of immunophenotypes and TCR repertoire
expression by flow cytometry
PBMC isolated from the patients and the recipient NOG mice as
described above were incubated for 30 min on ice with a mixture of
appropriate combinations of fluorescently labeled monoclonal
antibodies. After washing, five-color flow-cytometric analysis was
carried out with the Cytomics FC500 analyzer (Beckman Coulter).
The following directly labeled antibodies were used: phycoerythrin
(PE)-conjugated antibodies to CD3, CD8, and TCRa/b, fluores-
cein isothiocyanate (FITC)-conjugated antibodies to CD3, CD4,
CD8, CD19, TCRVc9, TCRVd2, and TCRc/d, and Phycoery-
thrin Texas Red (ECD)-conjugated antibody to CD45RO from
Beckman Coulter; PE-conjugated antibodies to CD16, CD40, and
CD40L, and FITC-conjugated antibody to CD56 from BD
Pharmingen. TCR Vb repertoire analysis was performed with the
Multi-analysis TCR Vb antibodies Kit (Beckman Coulter) accord-
ing to the procedure recommended by the manufacturer.
Treatment of mice with the OKT-4 antibody
NOG mice were injected intravenously with 5610
6 PBMC
isolated from the CAEBV patient 3 (CD8 type) or 8 (NK type) and
were subsequently injected intravenously with 100 mg of the
OKT-4 antibody on the same day of transplantation. Additional
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and route for the following three consecutive days. Peripheral
blood EBV DNA load was then monitored every week. Mice were
finally sacrificed four weeks post-transplantation and applied for
pathological and virological analyses.
Quantification of EBV DNA by real time PCR and analysis
of EBV gene expression by RT-PCR
Quantification of EBV DNA was carried out by real-time
quantitative PCR assay based on the TaqMan system (Applied
Biosystems), as described [54]. Analysis of EBV gene expression by
RT-PCR was carried out as previously described with the following
primers [55]. EBNA1: sense, gatgagcgtttgggagagctgattctgca; anti-
sense, tcctcgtccatggttatcac. EBNA2: sense, agaggaggtggtaagcggttc;
antisense, tgacgggtttccaagactatcc. LMP1: sense, ctctccttctcctcctcttg;
antisense, caggagggtgatcatcagta. LMP2A: sense, atgactcatctcaaca-
cata; antisense, catgttaggcaaattgcaaa. LMP2B: sense, cagtgtaatctg-
cacaaaga; antisense, catgttaggcaaattgcaaa. EBER1: sense, agcacc-
tacgctgccctaga; antisense, aaaacatgcggaccaccagc. Cp-EBNA1:
sense,cactacaagacctacgcctctccattcatc; anti sense, ttcggtctccccta-
ggccctg. Wp/Cp-EBNA1: sense, tcagagcgccaggagtccacacaaat; an-
tisense, ttcggtctcccctaggccctg. Qp-EBNA1: sense, aggcgcggga-
tagcgtgcgctaccgga; antisense, tcctcgtccatggttatcac. RT-PCR prim-
ers for b-actin were purchased from Takara (Osaka, Japan).
Histopathology, EBER ISH, and immunohistochemistry
Tissue samples were fixed in 10% buffered formalin, embedded
in paraffin, and stained with hematoxylin and eosin. For
phenotypic analysis of engrafted lymphocytes, immunostaining
for CD3, CD8 (Nichirei), CD45RO, and CD20 (DAKO) was
performed on paraffin sections. EBV was detected by in situ
hybridization (ISH) with EBV small RNA (EBER) probe.
Immunohistochemistry and ISH were performed on an automated
stainer (BENCHMARK XT, Ventana Medical Systems) accord-
ing to the manufacturer’s recommendations. To determine the cell
lineage of EBV infected cells, paraffin sections were applied to
double staining with EBER ISH and immunohistochemistry.
Immediately following EBER ISH, immunostaining for CD45RO
or CD20 was performed. Photomicrographs was acquired with a
OLYMPUS BX51 microscope equipped with 40x/0.75 and 20x/
0.50 Uplan Fl objective lens, a Pixera Penguin 600CL digital
camera (Pixera), and Viewfinder 3.01 (Pixera) for white balance,
contrast, and brightness correction.
Quantification of cytokines
The levels of human IL-8, IFN-c, and RANTES in plasma
samples were measured with the Enzyme-linked immunosorbent
assay (ELISA) kit provided by R&D Systems following instructions
provided by the manufacturer.
Accession numbers
The Swiss-Prot accession numbers for the proteins described in
this article are as follows: P13501 for RANTES; P10145 for IL-8;
P01579 for IFN-c; P03211 for EBNA1; P12978 for EBNA2;
P12977 for EBNA3; P03230 for LMP1; and Q66562 for LMP2.
The DDBJ accession number for EBER is AJ315772.
Supporting Information
Figure S1 Changes in the body weight of NOG mice
transplanted with PBMC derived from patients with CAEBV or
EBV-HLH. Body weight of the five CAEBV mice shown in
Figure 1A (transplanted with PBMC from the patient 1, 3, 5, and
9, and with the CD4
+ fraction from the patient 1, respectively) and
two EBV-HLH mice shown in Figure 6A (both transplanted with
PBMC from the patient 11) were recorded weekly.
(TIF)
Figure S2 Histopathological analysis of a control NOG mouse. A. a
NOG mouse without xenograft. A 20-week old female NOG mouse
was sacrificed and examined as a reference. No human cells are
identified in these tissues. Upper panels: liver tissue was stained with
hematoxylin-eosin (HE), antibodies specific to human CD3 or CD20,
or by ISH with an EBER probe; the rightmost panel is a double
staining with EBER and human CD45RO. Bottom panels: EBER
ISH in the spleen, kidney, and small intestine. B. a NOG mouse
transplanted with PBMC of a healthy EBV carrier. A six-week old
female NOG mouse was transplanted with 5610
6 PBMC isolated
from a normal EBV-seropositive person and sacrificed at eight weeks
post-transplantation for histological analysis. Liver and Spleen tissues
were stained with HE, antibodies specific to human CD3 or CD20, or
by ISH with an EBER probe. No EBER-positive cells were identified
in these tissues.Original magnification is 6200 for both A and B.
(TIF)
Table S1 EBV DNA load in lymphocyte subsets of a patient
with CAEBV and a corresponding mouse derived from her
PBMC.
(DOC)
Table S2 EBV DNA load in lymphocyte subsets of a patient
with EBV-HLH and a corresponding mouse derived from his
PBMC.
(DOC)
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